2023
Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventions
2020
Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis
Shrestha R, Altice FL, DiDomizio E, Sibilio B, Ranjit YS, Copenhaver MM. Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis. Patient Preference And Adherence 2020, 14: 107-118. PMID: 32021122, PMCID: PMC6971384, DOI: 10.2147/ppa.s236794.Peer-Reviewed Original ResearchPre-exposure prophylaxisHIV risk reductionHIV preventionText messaging servicePrimary HIV preventionHIV prevention strategiesOpioid-dependent peopleReminder text messagesWeekly text messagesPost-intervention assessmentRisk reductionForty HIVPrEP adherenceText messagesSMS remindersRisk groupsText remindersPrevention strategiesUnderserved populationsMHealth technologiesAcceptability studyHealth carePreventionProphylaxisPreliminary evidence
2019
Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study
Shrestha R, Altice FL, Sibilio B, Ssenyonjo J, Copenhaver MM. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. Contemporary Clinical Trials 2019, 82: 77-84. PMID: 31229618, PMCID: PMC6639056, DOI: 10.1016/j.cct.2019.06.012.Peer-Reviewed Original ResearchConceptsBio-behavioral interventionHIV risk reductionOpioid-dependent peopleMethadone maintenance programPrEP adherenceHIV transmission risk reductionFirst prospective trialPre-exposure prophylaxisHIV prevention strategiesOngoing drug useRisk reductionBehavioral skills modelProspective trialSecondary outcomesPrimary outcomeRisk reduction outcomesHIV riskWeek 20Prevention strategiesUnmet needDrug useHybrid type IBio-behavioral approachProcess evaluationAdherence
2017
Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research
Shrestha R, Altice F, Karki P, Copenhaver M. Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Frontiers In Immunology 2017, 8: 561. PMID: 28553295, PMCID: PMC5425476, DOI: 10.3389/fimmu.2017.00561.Peer-Reviewed Original ResearchNeurocognitive impairmentHigh-risk drug usersBehavioral interventionsHigh-risk PWUDHIV prevention behavioral interventionBiobehavioral approachHIV risk reductionHIV prevention interventionsDrug treatment settingsFormative researchHIV prevention effortsTarget populationPrEP adherencePrEP uptakeRisk reduction outcomesHIV preventionDrug treatmentPrevention interventionsFocus groupsTreatment settingsDrug usersRecovery programStructured focus groupsRisk behaviorsTarget population membersInterest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program
Shrestha R, Karki P, Copenhaver M. Interest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program. AIDS Care 2017, 29: 1144-1148. PMID: 28478706, PMCID: PMC6081193, DOI: 10.1080/09540121.2017.1325439.Peer-Reviewed Original ResearchConceptsHigh-risk PWUDMethadone maintenance programHIV preventionMedication remindersHIV risk reduction informationRisk behaviorsSex-related risk behaviorsHigh-risk drug usersMHealth technologiesHIV prevention toolHIV risk reductionHIV prevention approachesHIV risk behaviorsDrug treatment settingsRisk Behavior AssessmentHIV prevention effortsHIV-negative PWUDUse of mHealthNew intervention strategiesDepressive symptomsTreatment settingsDrug usersHealthcare providersMultivariate analysisPrevention effortsCorrelates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment
Shrestha R, Karki P, Altice FL, Huedo-Medina TB, Meyer JP, Madden L, Copenhaver M. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug And Alcohol Dependence 2017, 173: 107-116. PMID: 28214391, PMCID: PMC5366273, DOI: 10.1016/j.drugalcdep.2016.12.023.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisHIV risk reductionDrug injectionHIV riskRisk behaviorsHigh-risk drug usersHigh-risk PWUDOpioid-dependent personsHIV prevention approachesRecent risk behaviorsCross-sectional studyConsistent condom useHigh-risk behaviorsRisk reductionCorrelates of willingnessPrEP deliveryMethadone treatmentIndependent correlatesMethadone programsSafe drugElevated riskCasual partnersNeurocognitive impairmentDrug usersKey populations